Yang CH - Search Results

1

Hope and its relationship with treatment/ physical related factors in lung cancer patients receiving immunotherapy.

Hsu CC, Lee YH, Chen MR, Yang CH, Shih JY, Liao WY, Hsiao MP, Lai YH. Hsu CC, et al. Among authors: yang ch. J Formos Med Assoc. 2024 Jul 5:S0929-6646(24)00299-7. doi: 10.1016/j.jfma.2024.06.023. Online ahead of print. J Formos Med Assoc. 2024. PMID: 38971711 Free article.

2

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.

Su WP, Yang CH, Yu CJ, Shih JY, Hsu C, Yang PC. Su WP, et al. Among authors: yang ch, yang pc. J Formos Med Assoc. 2005 Aug;104(8):557-62. J Formos Med Assoc. 2005. PMID: 16193176

3

Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer.

Lee JH, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH. Lee JH, et al. Among authors: yang ch. J Formos Med Assoc. 2010 May;109(5):338-44. doi: 10.1016/S0929-6646(10)60061-7. J Formos Med Assoc. 2010. PMID: 20497866 Free article.

4

Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.

Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC. Chen KY, et al. Among authors: yang ch, yang pc. J Thorac Oncol. 2010 Jan;5(1):82-9. doi: 10.1097/JTO.0b013e3181c09b28. J Thorac Oncol. 2010. PMID: 19884854 Free article.

5

Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.

Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, Yang PC. Hsu CL, et al. Among authors: yang ch, yang pc. BMC Cancer. 2012 Jun 13;12:241. doi: 10.1186/1471-2407-12-241. BMC Cancer. 2012. PMID: 22695392 Free PMC article.

6

Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers.

Chen JP, Lo Y, Yu CJ, Hsu C, Shih JY, Yang CH. Chen JP, et al. Among authors: yang ch. Lung Cancer. 2008 Apr;60(1):92-97. doi: 10.1016/j.lungcan.2007.09.004. Epub 2007 Oct 23. Lung Cancer. 2008. PMID: 17936403

7

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Wu JY, et al. Among authors: yang ch, yang pc. Clin Cancer Res. 2008 Aug 1;14(15):4877-82. doi: 10.1158/1078-0432.CCR-07-5123. Clin Cancer Res. 2008. PMID: 18676761

8

Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.

Wu JY, Yang CH, Hsu YC, Yu CJ, Chang SH, Shih JY, Yang PC. Wu JY, et al. Among authors: yang ch, yang pc. Clin Lung Cancer. 2010 Jul 1;11(4):257-63. doi: 10.3816/CLC.2010.n.033. Clin Lung Cancer. 2010. PMID: 20630828

9

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Wu JY, et al. Among authors: yang ch, yang pc. Clin Cancer Res. 2011 Jun 1;17(11):3812-21. doi: 10.1158/1078-0432.CCR-10-3408. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531810

10

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Yang CH, et al. Among authors: yang pc. J Clin Oncol. 2008 Jun 1;26(16):2745-53. doi: 10.1200/JCO.2007.15.6695. J Clin Oncol. 2008. PMID: 18509184 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,174 results

Search Page

Filters